Pemetrexed safety and pharmacokinetics in patients with third-space fluid

Nicolas J Dickgreber, Jens Benn Sørensen, Luis G Paz-Ares, Tine Kjestrup Schytte, Jane E Latz, Karen B Schneck, Yuan Zheng, José Miguel Sanchez-Torres

Research output: Contribution to journalJournal articleResearchpeer-review

27 Citations (Scopus)

Abstract

Pemetrexed is established as first-line treatment with cisplatin for malignant pleural mesothelioma and advanced nonsquamous non-small-cell lung cancer (NSCLC) and as single-agent second-line treatment for nonsquamous NSCLC. Because the structure and pharmacokinetics of pemetrexed are similar to those of methotrexate, and methotrexate is associated with severe toxicity in patients with third-space fluid (TSF), the safety of pemetrexed in patients with TSF was evaluated.
Original languageEnglish
JournalClinical Cancer Research
Volume16
Issue number10
Pages (from-to)2872-80
Number of pages9
ISSN1078-0432
DOIs
Publication statusPublished - 15 May 2010

Cite this